{"id":15192,"date":"2024-05-31T11:40:02","date_gmt":"2024-05-31T11:40:02","guid":{"rendered":"https:\/\/cansearch.ch\/?page_id=15192"},"modified":"2024-05-31T11:41:28","modified_gmt":"2024-05-31T11:41:28","slug":"3-project-on-neuroblastoma","status":"publish","type":"page","link":"https:\/\/cansearch.ch\/en\/3-project-on-neuroblastoma\/","title":{"rendered":"3.\tProject on Neuroblastoma"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1456px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_5 1_5 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:20%;--awb-margin-top-large:0px;--awb-spacing-right-large:9.6%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:9.6%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.88%;--awb-width-medium:100%;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><h1><a name=\"_Toc166016247\"><\/a><span style=\"color: #e05843;\">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Project on Neuroblastoma<\/span><\/h1>\n<h3><a name=\"_Toc108788948\"><\/a>Evaluation of the in vivo efficacy of PRIMA-1MET and its synergistic interactions with combined inhibition of RAS-MAPK and AKT-mTOR in neuroblastoma<\/h3>\n<p>Neuroblastoma (NB) is the most common extracranial solid tumor in children, accounting for 7 to 8% of all childhood malignancies and 15% of all cancer-related deaths in this population. It is the most frequently diagnosed cancer during early childhood, with a median age at diagnosis of around 19 months. While 90% of patients are under 5 years old, NB is very rare after the age of 10. Metastatic disease is present in approximately 50% of cases.<\/p>\n<p>Children in the very low-risk subgroup have an expected long-term survival rate of 99 to 100%, while patients in the high-risk subgroup have a long-term survival rate of less than 50% despite intensive multimodal therapy including surgery, high-dose chemotherapy with autologous stem cell transplantation, radiotherapy, and immunotherapy. Therefore, new therapies for the high-risk subgroup are urgently needed.<\/p>\n<p>In recent years, the Neuroblastoma Group of the CANSEARCH research platform has focused on finding new treatment options for patients with neuroblastoma, particularly aggressive in metastatic forms. We have published very interesting results, notably on a small molecule, PRIMA-1MET (APR-246 or eprenetapopt), known to reactivate the p53 protein and its interactions with various signaling pathways important in neuroblastomagenesis.<\/p>\n<p>With the advent of CRISPR\/Cas9 technology, we have access to a new tool to investigate new avenues, particularly in the field of synthetic lethality.<\/p>\n<p>The aim of our current project is to develop CRISPR\/Cas9 library screening technology in neuroblastoma to identify additional synergistic genetic targets in the context of established therapies in neuroblastoma, especially with eprenetapopt, ALK inhibitors, and cisplatin.<\/p>\n<p>In addition to these activities, we will also continue to analyze relevant publicly available data from the INRG consortium to study the clinical importance of certain genetic markers and their combination.<\/p>\n<\/div><div class=\"fusion-content-boxes content-boxes columns row fusion-columns-1 fusion-columns-total-1 fusion-content-boxes-1 content-boxes-icon-with-title content-left\" style=\"--awb-hover-accent-color:#9e9e9e;--awb-circle-hover-accent-color:#9e9e9e;--awb-item-margin-bottom:40px;\" data-animationOffset=\"top-into-view\"><div style=\"--awb-backgroundcolor:var(--awb-custom_color_2);\" class=\"fusion-column content-box-column content-box-column content-box-column-1 col-lg-12 col-md-12 col-sm-12 fusion-content-box-hover content-box-column-last content-box-column-last-in-row\"><div class=\"col content-box-wrapper content-wrapper-background link-area-link-icon icon-hover-animation-fade\" data-animationOffset=\"top-into-view\"><div class=\"fusion-clearfix\"><\/div><div class=\"content-container\">\n<p><em>What does this study bring to patients?<\/em><\/p>\n<p><em>The Neuroblastoma project helps improve understanding of how cellular signaling pathways function within neuroblastoma tumor cells and identify important factors to better understand the aggressive behavior of this disease and develop better therapeutic strategies.<\/em><\/p>\n<\/div><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":14,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"ngg_post_thumbnail":0,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-15192","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/cansearch.ch\/en\/wp-json\/wp\/v2\/pages\/15192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cansearch.ch\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cansearch.ch\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cansearch.ch\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/cansearch.ch\/en\/wp-json\/wp\/v2\/comments?post=15192"}],"version-history":[{"count":2,"href":"https:\/\/cansearch.ch\/en\/wp-json\/wp\/v2\/pages\/15192\/revisions"}],"predecessor-version":[{"id":15194,"href":"https:\/\/cansearch.ch\/en\/wp-json\/wp\/v2\/pages\/15192\/revisions\/15194"}],"wp:attachment":[{"href":"https:\/\/cansearch.ch\/en\/wp-json\/wp\/v2\/media?parent=15192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}